Eli Lilly and Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 9.32 B

Eli Lilly and Company Operating Cash Flow is USD 9.32 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 153.50% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Eli Lilly and Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 3.68 B, a -41.80% change year over year.
  • Eli Lilly and Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 6.32 B, a -21.66% change year over year.
  • Eli Lilly and Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 8.06 B, a 3.17% change year over year.
  • Eli Lilly and Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 7.81 B, a 59.23% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities